Mereo BioPharma Group plc (Mereo) (MREO): Price and Financial Metrics
MREO Price/Volume Stats
| Current price | $2.78 | 52-week high | $4.36 |
| Prev. close | $2.78 | 52-week low | $0.92 |
| Day low | $2.76 | Volume | 748,300 |
| Day high | $2.88 | Avg. volume | 1,593,528 |
| 50-day MA | $3.27 | Dividend yield | N/A |
| 200-day MA | $2.29 | Market Cap | 347.46M |
MREO Stock Price Chart Interactive Chart >
Mereo BioPharma Group plc (Mereo) (MREO) Company Bio
Mereo BioPharma Group plc (Mereo) operates as a clinical stage biopharmaceutical company. The Company develops medicines for rare and specialty diseases. Mereo serves the healthcare sector globally.
Latest MREO News From Around the Web
Below are the latest news stories about MEREO BIOPHARMA GROUP PLC that investors may wish to consider to help them evaluate MREO as an investment opportunity.
Ultragenyx (RARE) Q3 Earnings and Revenues Miss EstimatesUltragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook. |
Mereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateLONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information. Recent Program Developments Setrusumab (UX143) On October 14, 2023, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (“Mereo” or the “Company”) announced interim data from the Phase 2 portion |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! |
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase |
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) October 13-16, 2023, in Vancouver, British Columbia. Ultragenyx and its collaborators will present late-breaking presentations on new, updated data from the Phase 2 portion of the |
MREO Price Returns
| 1-mo | -5.76% |
| 3-mo | -29.08% |
| 6-mo | 53.59% |
| 1-year | 126.02% |
| 3-year | -21.69% |
| 5-year | -51.65% |
| YTD | 20.35% |
| 2023 | 208.00% |
| 2022 | -53.13% |
| 2021 | -55.31% |
| 2020 | 9.15% |
| 2019 | N/A |
Loading social stream, please wait...